LRLaongthip Ruknarong

Laongthip Ruknarong

*This is an algorithmically generated author record based on publicly available information.

Laongthip Ruknarong has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    14-Deoxy-11,12-didehydroandrographolide Promotes Ex Vivo Expansion of Umbilical Cord Blood Stem Cells through Stemness-Related Gene Regulation

    by Laongthip Ruknarong, Nareerat Sutjarit, Nittaya Boonmuen, Puckjira Iaocharoen, Tippawan Duangsong, Wachirachai Pabuprapap, Apichart Suksamrarn, Duangrat Tantikanlayaporn

    Umbilical cord blood (UCB) is a valuable alternative source of hematopoietic stem and progenitor cells (HSPCs) for allogeneic transplantation. However, the limited number of HSPCs that can be obtained from a single UCB unit remains a significant clinical challenge. Therefore, strategies to enhance the ex vivo expansion of functional HSPCs are of considerable interest. A key requirement for improving the success of HSC-based therapies, including transplantation and gene editing, is the ability to expand or preserve functional human HSCs during ex vivo culture. In this study, we demonstrate that 14-deoxy-11,12-didehydroandrographolide (14-DDA), a diterpenoid isolated from Andrographis paniculata, significantly promotes the ex vivo expansion of UCB-derived CD34+ cells and enriches for primitive HSPC subsets (CD34+CD38–CD90+). Functional assays reveal that 14-DDA enhances colony-forming unit output, which preserves multilineage differentiation potential. Furthermore, 14-DDA activates the Wnt/β-catenin signaling pathway, indicating a potential mechanism for supporting stem cell self-renewal. Gene expression profiling reveals upregulation of stemness- and proliferation-associated genes, while suppression of genes is related to differentiation, stress responses, and oncogenesis. These findings suggest that 14-DDA promotes the expansion of functional HSPCs while maintaining their primitive phenotype and reducing oncogenic risk, highlighting its potential as a natural small molecule for enhancing hematopoietic stem cell-based therapies.

  • Genipin Analogue (G300) Inhibits Adipogenic Differentiation of Human Bone Marrow-Derived Mesenchymal Stem Cells through the Suppression of Adipogenic Promoting Factors

    by Nittaya Boonmuen, Kanoknetr Suksen, Mintra Kaewkittikhun, Laongthip Ruknarong, Patamawadee Silalai, Rungnapha Saeeng, Arthit Chairoungdua, Sunhapas Soodvilai, Duangrat Tantikanlayaporn

    While obesity is a well-known health threatening condition worldwide, effective pharmacological interventions for obesity suppression have been limited due to adverse effects. Therefore, it is important to explore alternative medical treatments for combating obesity. Inhibition of the adipogenesis process and lipid accumulation are critical targets for controlling and treating obesity. Gardenia jasminoides Ellis is a traditional herbal remedy for various ailments. A natural product from its fruit, genipin, has major pharmacological properties; it is anti-inflammatory and antidiabetic. We investigated the effects of a genipin analogue, G300, on adipogenic differentiation in human bone marrow mesenchymal stem cells (hBM-MSCs). G300 suppressed the expression of adipogenic marker genes and adipokines secreted by adipocytes at concentrations of 10 and 20 mu M, which effectively reduced the adipogenic differentiation of hBM-MSCs and lipid accumulation in adipocytes. It also improved adipocyte function by lowering inflammatory cytokine secretion and increasing glucose uptake. For the first time, we show that G300 has the potential to be a novel therapeutic agent for the treatment of obesity and its related disorders.